Launch Catch-Up — Research Reported October 23, 2026
An experimental cancer treatment showed activity in an early human trial involving patients whose tumors had resisted other therapies, the National Institutes of Health reported October 23.
The drug, invikafusp alfa, or invika, is designed to stimulate selected populations of tumor-fighting T cells rather than activating T cells broadly.
NIH’s account describes phase 1 and initial phase 2 results. Among 27 participants receiving the dose selected by researchers, disease did not progress in 16, and four had reductions greater than 30% in the size of targeted tumors.
The study involved several cancer types. These early observations do not establish that the treatment cures cancer, works for every patient or provides the same benefit across tumor types.
Researchers reported flu-like side effects in several participants. NIH described those effects as generally manageable with supportive care and additional medication.
The agency said the findings support further study, including possible combinations with other treatments. The trial remains experimental; a Fast Track designation discussed in the announcement accelerates evaluation and is not marketing approval.
This report summarizes NIH’s dated research account, without making an individual treatment recommendation.
Sources: NIH — October 23 trial report: https://www.nih.gov/news-events/news-releases/precision-t-cell-therapy-stalls-treatment-resistant-cancers-clinical-trial